274 related articles for article (PubMed ID: 27110718)
1. Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay.
Blokzijl A; Chen LE; Gustafsdottir SM; Vuu J; Ullenhag G; Kämpe O; Landegren U; Kamali-Moghaddam M; Hedstrand H
PLoS One; 2016; 11(4):e0154214. PubMed ID: 27110718
[TBL] [Abstract][Full Text] [Related]
2. SOX10 expression in malignant melanoma, carcinoma, and normal tissues.
Mohamed A; Gonzalez RS; Lawson D; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):506-10. PubMed ID: 23197006
[TBL] [Abstract][Full Text] [Related]
3. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
4. Can SOX-10 or KBA.62 Replace S100 Protein in Immunohistochemical Evaluation of Sentinel Lymph Nodes for Metastatic Melanoma?
Vrotsos E; Alexis J
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):26-9. PubMed ID: 25611246
[TBL] [Abstract][Full Text] [Related]
5. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.
Gebhardt C; Lichtenberger R; Utikal J
J Dtsch Dermatol Ges; 2016 Feb; 14(2):158-64. PubMed ID: 26819111
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
7. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of melanocytic markers for immunocytochemical evaluation of lymph-node melanoma metastases on cytological samples.
Ronchi A; Zito Marino F; Toni G; Pagliuca F; Russo D; Signoriello G; Moscarella E; Brancaccio G; Argenziano G; Franco R; Cozzolino I
J Clin Pathol; 2022 Jan; 75(1):45-49. PubMed ID: 33509946
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
10. [Molecular classification and markers of malignant melanoma].
Tímár J; Hársing J; Somlai B
Magy Onkol; 2013 Jun; 57(2):73-8. PubMed ID: 23795351
[TBL] [Abstract][Full Text] [Related]
11. Serum level of S100B in vitiligo patients: Is it a marker of disease activity?
Badran AY; Gomaa AS; El-Mahdy RI; El Zohne RA; Kamal DT; Abou-Taleb DAE
Australas J Dermatol; 2021 Feb; 62(1):e67-e72. PubMed ID: 32951206
[TBL] [Abstract][Full Text] [Related]
12. Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.
Su Z; Zheng X; Zhang X; Wang Y; Zhu S; Lu F; Qu J; Hou L
J Dermatol Sci; 2017 Mar; 85(3):216-225. PubMed ID: 27955842
[TBL] [Abstract][Full Text] [Related]
13. SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes.
Willis BC; Johnson G; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):109-12. PubMed ID: 25356946
[TBL] [Abstract][Full Text] [Related]
14. Sox10: a pan-schwannian and melanocytic marker.
Nonaka D; Chiriboga L; Rubin BP
Am J Surg Pathol; 2008 Sep; 32(9):1291-8. PubMed ID: 18636017
[TBL] [Abstract][Full Text] [Related]
15. S100B Is a Potential Disease Activity Marker in Nonsegmental Vitiligo.
Speeckaert R; Voet S; Hoste E; van Geel N
J Invest Dermatol; 2017 Jul; 137(7):1445-1453. PubMed ID: 28212812
[TBL] [Abstract][Full Text] [Related]
16. A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas.
Tacha D; Qi W; Ra S; Bremer R; Yu C; Chu J; Hoang L; Robbins B
Arch Pathol Lab Med; 2015 Apr; 139(4):530-6. PubMed ID: 25436903
[TBL] [Abstract][Full Text] [Related]
17. SOX10 expression in superficial spreading and nodular malignant melanomas.
Agnarsdóttir M; Sooman L; Bolander A; Strömberg S; Rexhepaj E; Bergqvist M; Ponten F; Gallagher W; Lennartsson J; Ekman S; Uhlen M; Hedstrand H
Melanoma Res; 2010 Dec; 20(6):468-78. PubMed ID: 20890226
[TBL] [Abstract][Full Text] [Related]
18. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo-like primary melanoma.
Lugo-Somolinos A; Sánchez JL; Garcia ME
Am J Dermatopathol; 2008 Oct; 30(5):451-4. PubMed ID: 18806487
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification.
Welinder C; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Breslin T; Rezeli M; Jansson B; Laurell T; Fehniger TE; Wieslander E; Pawlowski K; Marko-Varga G
J Proteome Res; 2014 Mar; 13(3):1315-26. PubMed ID: 24490776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
